V-Wave Ltd.

Johnson & Johnson raised its 2024 profit and sales forecast on Tuesday, following strong oncology drug sales and quarterly results that beat Wall Street expectations. During the quarter, J&J's global sales of cancer drugs increased by nearly 19%, including sales of multiple myeloma treatment Darzalex, which exceeded the $3 billion mark, an increase of 20.7%, or more than $500 million. According to analysts, Darzalex is expected to generate nearly $11 billion in revenue this year, compared with their previous estimate of $2.92 billion in the third quarter. Joe Wolk, Johnson & Johnson's chief financial officer, noted that continued adoption of the subcutaneous version of Darzalex significantly reduced the duration of treatment and received regulatory approval to expand its use, which provided strong support for the improved sales performance. However, the company also noted that the after-effects of Hurricane Helen impacted business in the final weeks of the quarter, particularly in affected areas such as western North Carolina and Florida. At the same time, the company is closely monitoring the shortage of intravenous fluids, a problem exacerbated by flooding in Helene that paralyzed Baxter International's new plant in Marion, North Carolina, limiting intravenous supplies nationwide. Tim Schmid, global chairman of J&J's medical devices business, said: "The recently announced shortage of intravenous saline, if sustained, could have an impact on surgical procedures across our portfolio." In the face of the challenges, the New Jersey-based healthcare group maintained a solid financial performance, raising its profit forecast for the year by 10 cents to $10.15 a share (excluding a 24-cent charge related to its acquisition of medical device maker V-Wave). The company also expects sales for the year to be in the range of $89.4 billion to $89.8 billion, up from its previous forecast range of $89.2 billion to $89.6 billion. However, after accounting for merger-related charges, the company now expects earnings per share in the range of $9.86 to $9.96, slightly lower than its previous forecast of $10 to $10.10. Despite the challenges, Johnson & Johnson's market performance remained strong, with shares rising nearly 3% to $166.14 on a day when the broader market was down. In addition, although sales of the best-selling psoriasis drug Stelara fell 6.6 percent to $2.68 billion in the third quarter, its performance still beat analysts' expectations of $2.43 billion. Stelara has long been an important growth engine for J&J, with analysts forecasting sales of more than $10 billion this year. By 2025, however, Stelara's sales are expected to fall to about $7 billion as competition for as many as six biosimilars intensifies in the U.S. market. Still, Johnson & Johnson is confident about its future, saying it is confident of achieving "more than $57 billion in pharmaceutical sales" by 2025. Analysts expect drug sales to reach $56.77 billion next year. Barclays analyst Matt Miksic believes the target seems reasonable given the strong performance of the pharmaceutical division this quarter. In addition, J&J's cancer cell therapy Carvykti also achieved strong results, with sales of $286 million, beating expectations of $239 million. Although tight supply has limited Carvykti's sales growth, J&J said it is actively taking steps to increase capacity at its New Jersey and Belgium plants to meet market demand. In the medical devices segment, quarterly sales rose 5.8 percent to $7.9 billion, showing solid growth even though the figure was slightly below analysts' expectations of $8.05 billion.

J&J Terminates RA and Leukemia Drug From Pipeline iStock, yuelan Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which brought in more than $3 billion. Johnson & Johnson released its third-quarter earnings report on Tuesday, touting strong revenue growth that exceeded Wall Street’s expectations—alongside a more optimistic full-year outlook. In Q3, the pharma generated nearly $22.5 billion in sales, representing 5.2% year-over-year growth—excluding the impact of translational currency—and beating the consensus estimate of nearly $22.2 billion. Adjusted earnings per share (EPS), on the other hand, dipped 9% year-on-year to $2.42, though still outperforming the $2.21 EPS that analysts were expecting, according to Seeking Alpha . J&J’s Innovative Medicine unit continued to be the main driver of its business, bringing in around $14.6 billion in Q3, accounting for around two-thirds of its total sales. Oncology remained J&J’s most lucrative segment, which brought in $5.38 billion in sales in the quarter. The multiple myeloma therapy Darzalex was the pharma’s top asset with more than $3 billion in reported sales worldwide. Jefferies analyst Peter Welford in a note to investors pointed out that Darzalex’s sales beat consensus expectations by 2%. Other high-performing assets in Q3 included the antidepressant nasal spray Spravato, which saw a nearly 55% jump in sales, and the CAR T therapy Carvykti , which surged almost 88% in the quarter. The prostate cancer treatment Erleada was also notable, growing 25.4% year-over-year to earn $790 million worldwide. While immunosuppressive drug Stelara also contributed heavily to J&J’s overall Q3 sales—raking in nearly $2.7 billion in the quarter—the blockbuster therapy is already seeing revenue erosion from mounting biosimilar competition. Its revenue was hit with a 6.6% decline from the same period in 2023. Guggenheim Securities analyst Vamil Divan said in an investor note that J&J’s strong Q3 showing is “mainly due to better-than-expected performance by assets such as Darzalex, Carvykti and Erleada,” adding that the miss in the pharma’s medtech division only partially offset the sales of its Innovative Medicine unit. “We do not believe the 3Q 2024 results fundamentally change the overall JNJ story, with investors likely focusing more on the performance of current growth drivers,” Divan wrote, referring to assets such as Carvykti, Spravato and the anti-inflammatory antibody Tremfya. Looking forward, J&J raised its full-year operational sales guidance to $89.4 billion to $89.9 billion, up from a previous range of $89.2 billion to $89.6 billion. However, adjusted operational EPS was lowered to $9.86 to $9.96, from a previous forecast of $10.00 to $10.00, to accommodate dilution from the recently closed acquisition of medical device maker V-Wave.

据外媒Endpoints 9月25日报道，强生正在逐步关闭其制药部门的心血管和代谢部门，该举动主要影响销售、营销和医学事务团队。 这是强生继去年关闭传染病和疫苗部门后的第二次大规模重组。本次重组主要影响心血管部门的商业工作，而非研发。这一变化促使强生在全球范围内裁员，并剥离了许多疫苗和预防项目。 心血管和代谢部门的核心产品是拜瑞妥（利伐沙班），这是强生与拜耳合作开发的抗凝药，曾是世界上最畅销的药物之一。但由于美国政府的医疗保险价格谈判，拜瑞妥的价格降低了62%。 强生的医疗器械部门在心血管领域的业务未受影响，仍在积极进行相关收购和研发活动： 今年8月份，强生将以6亿美元的预付款收购V-Wave。 今年4月，强生份以131亿美元现金收购Shockwave所有流通股，该公司专注于开发钙化心血管疾病治疗的产品，并全球首推产品“冲击波球囊导管”。 2022年，强生公司以166亿美元收购了医疗设备制造商Abiomed。该公司的王牌产品为Impella心脏泵。 2023年9月，强生宣布品牌焕新，将旗下医疗科技和制药两大业务整合至强生（Johnson & Johnson）名下。其中，制药业务杨森更名为强生创新制药（Johnson & Johnson Innovative Medicine）。这家制药公司一直淡化其心血管和代谢业务，将研发重点缩小到三个治疗领域：肿瘤学、免疫学和神经科学。 强生在2024年进行了多项收购和研发活动，包括收购Proteologix获得免疫学双抗资产、收购Numab获得IL-4R/IL-31双抗、收购Ambrx开发下一代ADC产品等。公司发言人表示，这是强生在复杂和快速变化的外部环境中适应和发展业务的必要举措。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。 转载/商务/投稿 | 联系微信 wfj_GM 商务合作 稿件征集 点击了解详情 往期回顾 1 5月| 20家药企裁员（附名单） 2 18亿美元，ADC又出海! 宜联生物宣布新授权 3 2024 ASCO| 默沙东/科伦TROP2 ADC、信达、礼新CLDN18.2 ADC数据公布